We compared the glycosaminoglycan content of human venous and arterial walls. The most abundant glycosaminoglycan in human veins is dermatan sulfate whereas chondroitin 4/6-sulfate is preponderant in arteries. The concentrations of chondroitin 4/6-sulfate and heparan sulfate are V4.8-and V2.5-fold higher in arteries than in veins whereas dermatan sulfate contents are similar in the two types of blood vessels. Normal and varicose saphenous veins do not differ in their glycosaminoglycan contents. It is known that certain glycosaminoglycan species from the arterial wall, mainly highmolecular-weight fractions of dermatan sulfate+chondroitin 4/6-sulfate have greater affinity for plasma LDL. These types of glycosaminoglycans can be identified on a LDL-affinity column. We now demonstrated that a similar population of glycosaminoglycan also occurs in veins, although with a lower concentration than in the arteries due to less chondroitin 4/6-sulfate with affinity for LDL. The concentrations of dermatan sulfate species, which interact with LDL, are similar in arteries and veins. The presence of these glycosaminoglycans with affinity to plasma LDL in veins raises interesting questions concerning the role of these molecules in the pathogenesis of atherosclerosis. Possibly, the presence of these glycosaminoglycans in the vessel wall are not sufficient to cause retention of LDL and consequently endothelial dysfunction, but may require additional intrinsic factors and/or the hydrodynamic of the blood under the arterial pressure. ß
Introduction
The basic constituents of the walls of blood vessels are endothelial cells, smooth muscle cells, and extracellular matrix, including elastic elements, collagen, and proteoglycans. However, the architecture of the vessel walls varies with and re£ects distinct functional requirements at di¡erent locations. Thus, the relative amounts of the basic cellular and extracellular constituents vary along the vascular system owing to local adaptations to mechanical or metabolic needs. For example, in order to withstand the pulsatile and higher blood pressures in arteries, arterial walls are generally thicker than their venous counterparts. Veins have a larger overall diameter, a larger lumen and a thinner wall than the corresponding arteries [1] .
Vascular disease primarily a¡ects arteries, and of these, the most prevalent and clinically signi¢cant problem is atherosclerosis [2] . Veins have a relatively poor support and are predisposed to abnormal dilation and tortuous veins, known as varicose veins, produced by prolonged, increased intraluminal pressure and, to a lesser extent, by loss of support of the vessel walls. Nevertheless, when a segment of vein is transferred to the arterial system it undergoes physiological and pathological changes, including intimal thickening and atherosclerosis. This constitutes the major long-term complication of patients submitted to coronary artery bypass using grafts of autologous reversed vein. Many of these patients develop late recurrence of symptoms because of progression of atherosclerosis to the vein graft.
In the last years, we [3^6] and several other laboratories [7^10] have studied the glycosaminoglycan composition of normal and pathological arterial walls. High concentration of glycosaminoglycan was shown to occur in this tissue and a speci¢c population of high-molecular-weight chondroitin 4/6-sulfate+dermatan sulfate is probably involved in the retention and local deposition of plasma low-densitylipoprotein into the arterial wall [4, 5, 11, 12] . We now extend these studies to di¡erent types of normal and pathological veins. The purpose of the present study was not only to determine whether the glycosaminoglycan composition varies from arterial to vein and/ or with speci¢c anatomic location of the venous system, but also whether speci¢c populations of vein glycosaminoglycan have the ability to bind LDL.
The results require a careful interpretation due to di¡erences of cellular and extracellular components between arteries and veins [1] . Nevertheless, some basic aspects related to pathological processes may be clari¢ed with these results. For example, the absence of a population of glycosaminoglycan with the ability to bind LDL could explain the absence of atherosclerotic lesions in the vein walls. In contrast, the presence of these glycosaminoglycans in veins may indicate that additional intrinsic factors of the arterial bed and its blood-carrying functions in£u-ence the occurrence of lesions. Our experimental approach consisted of (1) a detailed characterization of glycosaminoglycan composition and its concentration in normal and pathological human veins; (2) analyses of vein glycosaminoglycan binding to plasma LDL; and (3) further characterization of the glycosaminoglycan samples after LDL binding.
Materials and methods

Materials
Human central veins (jugular, renal, subclavia, iliaca, cava, porta and pulmonary veins) and thoracic aortas were obtained from necropsies. Normal saphenous veins were obtained from patients undergoing coronary bypass surgery and varicose leg veins from patients undergoing vascular surgery. These patients were aged between 40 and 60 years old, had no severe diabetes, blood hypertension or extensive thromboembolic disease. All the samples were preserved in acetone until used. In the aorta samples, after removing the adventitial layer, only the segments containing the intima+media layers devoid of macroscopically visible atherosclerotic lesions, were used for glycosaminoglycan extraction. Samples were cut into small pieces and subjected to two changes of 10 volumes of chloroform:methanol (2:1, v/v) for 24 h each. The ¢nal defatted powder was obtained by drying this material under vacuum. Standard chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, dextran sulfate and cyanogen bromide-activated Sepharose 4B were purchased from Sigma Chemical Co. Chondroitin AC lyase (EC 4.2.2.5) and chondroitin ABC lyase (EC 4.2.2.4) were from Seikagaku American Inc.
Isolation of total vessel glycosaminoglycans
The chloroform/methanol-treated venous or arterial powder (100 mg, dry weight) was rehydrated in 3.7 ml of 0.1 M sodium acetate bu¡er (pH 5.0), containing 5 mM cysteine and 5 mM EDTA at 4 ‡C for 24 h. Thereafter, total glycosaminoglycans were isolated by proteolysis with papain, followed by subsequent cetylpyridinium and ethanol precipitations, as described previously [5, 6] . The ¢nal pellet was dried under vacuum and dissolved in 1.0 ml distilled water. Total glycosaminoglycan contents in the samples were estimated by determination of hexuronic acid concentration of the ¢nal solutions [13] . Under these conditions, papain digestion completely solubilized all vessel samples, and controls using known amounts of glycosaminoglycans showed that recovery from the subsequent cetylpyridinium and ethanol precipitation was greater than 90%.
Fractionation and characterization of the vessel glycosaminoglycans
Fractionation of the glycosaminoglycans was performed by anion exchange chromatography on a Mono Q-FPLC column. The eluted fractions were assayed by the metachromasy produced by sulfated glycosaminoglycans with 1,9-dimethyl methylene blue [14] and by hexuronic acid content using the carbazole reaction [13] . Fractions were pooled, dialyzed against distilled water, lyophilized and then dissolved in distilled water.
Sulfated glycosaminoglycans separated on the Mono Q-FPLC were identi¢ed by agarose gel electrophoresis. In this experiment glycosaminoglycans (V10 Wg) were applied to a 0.5% agarose gel in 0.05 M 1,3-diaminopropane/acetate bu¡er (pH 9.0) before and after subsequent treatments of the samples with chondroitin AC lyase, chondroitin ABC lyase and nitrous acid. After electrophoresis (120 V for 1 h), the glycosaminoglycans in the gel were ¢xed with 0.1% N-cetyl-N,N,N-trimethylammonium bromide in water, stained with 0.1% toluidine blue in acetic acid/ethanol/water (0.1:5:5, v/v), and washed for about 30 min in acetic acid/ethanol/water (0.1:5:5, v/v). The relative proportions of chondroitin 4/6-sulfate and dermatan sulfate were estimated by densitometry using a model GS-690 imaging densitometer (Bio-Rad Laboratories). Three replicate densitometric pro¢les were obtained for each sample. In terms of peak height and position, the replicates did not vary more than 5% from the pro¢les shown in the ¢gures.
The molecular weights of the glycosaminoglycan chains were estimated by polyacrylamide gel electrophoresis. Glycosaminoglycan samples (V10 Wg) were applied to a 6% 1-mm-thick polyacrylamide gel slab in 0.02 M sodium barbital bu¡er (pH 8.6). After electrophoresis (100 V for 30 min), the gel was stained with 0.1% toluidine blue in 1% acetic acid, and washed for about 4 h in 1% acetic acid. The molecular weight markers were the same as those used previously [15] . In a previous study [4] , we estimated the molecular weight of aortic glycosaminoglycans by gel ¢ltration and polyacrylamide gel electrophoresis. The two methods have nearly identical accuracy. But we used the latter method in this study because it requires a smaller amount of sample.
Isolation of LDL from plasma
LDL (d = 1.019^1.063 g/ml) was puri¢ed by the method of Havel et al. [16] , using human plasma obtained from healthy donors. After sequential ultracentrifugations in KBr, the LDL preparation was dialyzed at 4 ‡C against 0.9% NaCl containing 0.01% EDTA and 0.01% NaN 3 . Purity of LDL in this preparation was assessed by agarose gel electrophoresis in barbital bu¡er. The LDL migrated as a single band.
Interaction between LDL and glycosaminoglycans
Experiments on the interaction between LDL and vessel glycosaminoglycan were performed essentially as described elsewhere, using LDL-a⁄nity chromatography [3^6].
The LDL-a⁄nity column was constructed by coupling the ligand to CNBr-activated Sepharose 4B according to the protocol supplied with the product (Pharmacia). The e⁄cacy of the procedure used for binding LDL to Sepharose 4B was assessed by measuring the cholesterol content of the resin. A control column was prepared in the same way but without the lipoprotein. To avoid natural variations in LDL obtained from di¡erent individuals, LDL obtained from a single healthy donor was used for all a⁄nity columns. However, three replicate analyses of the same glycosaminoglycan mixture on LDL-a⁄nity columns prepared with LDL from di¡erent healthy donors replicates did not vary more than 10% in terms of the amounts of glycosaminoglycans retained by the columns and of chondroitin 4/6-sulfate:dermatan sulfate ratios in the retained fractions.
About 100 Wg (as hexuronic acid) of glycosaminoglycan in 1 ml of bu¡er was applied to LDL^Sephar-ose column (0.7U8.0 cm) pre-equilibrated with 5 mM Tris^HCl bu¡er (pH 7.4) containing 10 mM CaCl 2 . After the column was washed with 20 ml of the same bu¡er, the retained material was eluted using a linear NaCl gradient. Eluted fractions were analyzed by their metachromatic property [14] and by their hexuronic acid content [13] . A control column was made by identical treatment of the resin but omitting the lipoprotein. Aortic glycosaminoglycans were not signi¢cantly retained on this column (5% of the applied sample). See also Tovar et al. [17] .
Results
Glycosaminoglycan content of human veins
The total glycosaminoglycan content, as determined by the hexuronic acid assay, is signi¢cantly higher in the saphenous than in the several central veins (Table 1 ). In contrast, no di¡erence was observed between normal saphenous and varicose leg veins. Nevertheless, all types of veins included in this study had a signi¢cant lower content of glycosaminoglycan than thoracic aorta (Table 1) or other types of arteries that we had studied previously [5] , such as iliac and pulmonary arteries.
Chromatography on Mono Q-FPLC separates the glycosaminoglycans into three peaks, namely, the hyaluronic acid, heparan sulfate and dermatan sulfate +chondroitin 4/6-sulfate fractions, as exempli¢ed in Fig. 1A for normal saphenous vein. No variations were observed in the NaCl concentrations necessary for elution of the three peaks in di¡erent types of veins, but the relative amounts in each peak (based on hexuronic acid content) varied with the type of veins. The identities of the three fractions of glycosaminoglycans were established as follows: hyaluronic Tris^HCl bu¡er. The column was developed by a linear gradient of 0.15^1.5 M NaCl in the same bu¡er using a £ow rate of 0.45 ml/ min. Fractions of 0.5 ml were collected and assayed for metachromasia (a), hexuronic acid (b), and NaCl concentration (----). Fractions were pooled as indicated (horizontal bars) and precipitated with three volumes of ethanol. Recovered materials were identi¢ed as hyaluronic acid (HA), heparan sulfate (HS), and dermatan sulfate+chondroitin 4/6-sulfate (DS/CS), as described in the text. (B,C) Samples (V10 Wg) of heparan sulfate and dermatan sulfate+chondroitin 4/6-sulfate, puri¢ed on the Mono Q-FPLC, were applied to a 0.5% agarose gel in 0.05 M 1,3-diaminopropane/acetate bu¡er (pH 9.0). After electrophoresis, the glycosaminoglycans in the gel were ¢xed with 0.1% N-cetyl-N,N,N-trimethylammonium bromide and stained with toluidine blue (see Section 2). Standard glycosaminoglycans used were chondroitin 4-sulfate from whale cartilage, dermatan sulfate from pig skin and heparan sulfate from human aorta. The proportions of chondroitin 4/6-sulfate and dermatan sulfate were quanti¢ed by densitometry, and a typical pro¢le is shown in (C). The dermatan sulfate peak is crosshatched. Panels show typical chromatographic and electrophoretic pro¢les in terms of intensity and position of the bands, as observed among glycosaminoglycan samples from 14 saphenous veins. See [5, 6] for additional information about the methodology used in the experiments. acid is not detected by agarose gel electrophoresis but forms unsaturated non-sulfated disaccharide (vGlcUA-GlcNAc) by chondroitin AC lyase digestion (not shown). The heparan sulfate fraction migrated on agarose gel electrophoresis as the standard of heparan sulfate (Fig. 1B) , resisted chondroitin AC or ABC lyase digestion, but was degraded by deamination cleavage with nitrous acid (not shown). The third fraction from Mono Q-FPLC contained a mixture of dermatan sulfate and chondroitin 4/6-sulfate, as demonstrated by agarose gel electrophoresis (Fig.  1B) . Incubation of this fraction with chondroitin AC lyase only degraded the glycosaminoglycan with an electrophoretic migration similar to that of standard chondroitin 4/6-sulfate, and generated a peak that co-migrates with the standard of dermatan sulfate. Finally, treatment with chondroitin ABC lyase degraded the glycosaminoglycans producing an electrophoretic migration similar of standard of chondroitin 4/6-sulfate and dermatan sulfate (not shown). The relative proportions of these two glycosaminoglycans were quanti¢ed by densitometry of the agarose gel electrophoresis, and a typical pro¢le for glycosaminoglycans extracted from normal saphenous vein is shown in Fig. 1C .
Dermatan sulfate+chondroitin 4/6-sulfate from veins and arteries were eluted from Mono Q-FPLC with similar NaCl concentrations (compare data of Fig. 1A with those of reference [6] . Thus, these glycosaminoglycans from the two types of vessels had similar charge density. In addition, dermatan sulfate +chondroitin 4/6-sulfate from veins and arteries did not yield signi¢cant amounts ( s 5%) of non-sulfated or disulfated disaccharides after digestion with chondroitin ABC lyase.
From the data on the relative proportions of the three fractions of glycosaminoglycans estimated on Mono Q-FPLC (Fig. 1A) , the relative proportion Table 2 Relative proportions of dermatan sulfate and chondroitin 4/6-sulfate in fractions from LDL-a⁄nity chromatography
Vessel
Relative proportion (%)
Retained on the LDL-column Non-retained on the LDL-column The dermatan sulfate+chondroitin 4/6-sulfate fractions from ion exchange chromatography were applied to LDL-a⁄nity columns and the subjected to elution with an increasing linear gradient of NaCl. Obtained fractions were pooled as retained and non-retained fractions (see Fig. 3 ) and the proportions of these two fractions were determined based on the hexuronic acid content. of chondroitin 4/6-sulfate and dermatan sulfate (Fig.  1C) and total glycosaminoglycan content (Table 1) , the concentrations of the four species in human veins and arteries could be estimated (Fig. 2) . The amount of hyaluronic acid was quite variable and we could not establish signi¢cant di¡erences among vein samples (data not shown). Clearly, the most abundant glycosaminoglycan in human veins is dermatan sulfate whereas chondroitin 4/6-sulfate is preponderant in thoracic aortas (Fig. 2) . In fact, chondroitin 4/6-sulfate is V4^8-fold more concentrated in human arteries than in veins (Fig. 2, CS) , whereas the di¡er-ences in the concentration of dermatan sulfate between the two types of vessels are not very pro- Fig. 3 . LDL-a⁄nity chromatography of venous and arterial dermatan sulfate+chondroitin 4/6-sulfate. About 100 Wg (as hexuronic acid) of dermatan sulfate+chondroitin 4/6-sulfate from normal and varicose saphenous vein and from thoracic aorta, puri¢ed by Mono Q-FPLC (see Fig. 1 ), was applied to an LDL^Sepharose column (0.7U8.0 cm) and eluted using a linear gradient (see Section 2). Eluted fractions were assayed for metachromasia (a), hexuronic acid (b) and NaCl concentration (öö). Fractions corresponding to retained (R) and non-retained (non-R) glycosaminoglycans were pooled as indicated (horizontal bars) and precipitated with three volumes of absolute ethanol. The precipitated glycosaminoglycans were dissolved in distilled water and used for the experiments shown in Table 3 and Fig. 4 . Fig. 2 . Glycosaminoglycan contents in thoracic aorta and in normal and varicose veins. Contents of chondroitin 4/6-sulfate (CS), dermatan sulfate (DS) and heparan sulfate (HS) are given in Wg of hexuronic acid per mg of dry, defatted tissue. Hexuronic acid content in total glycosaminoglycan extract was measured using carbazole reaction (see Table 1 ). In combination with the data from anion exchange chromatography (Fig. 1A ) and agarose gel electrophoresis (Fig. 1C) , these data permit estimation of the concentrations of the individual glycosaminoglycan species in the several types of vessels. *P 6 0.002; **not signi¢cant.
nounced (Fig. 2, DS) . Again, the contents of the three species of sulfated glycosaminoglycans are signi¢cantly higher in the saphenous than in the central veins whereas no di¡erence was observed between normal and varicose leg veins.
Interaction between plasma LDL and glycosaminoglycans extracted from the human veins
A direct measurement of the interaction between the glycosaminoglycans extracted from vein wall and plasma LDL was undertaken using a⁄nity chromatography. A column was prepared by coupling human LDL to Sepharose 4B, and to this column the puri¢ed dermatan sulfate+chondroitin 4/6-sulfate fractions were applied (Fig. 3) . Vessel heparan sulfate is virtually not retained. To obtain a quantitative index of the interaction with LDL, we compared the amount of total dermatan sulfate+chondroitin 4/6-sulfate retained on the a⁄nity column with the total amount applied. The proportion of retained glycosaminoglycan is similar for aortic aorta and saphenous vein, including pathological varicose vein (Table 2) , and all glycosaminoglycans were eluted from the column with the same concentration of NaCl (Fig. 3) .
The proportions of dermatan sulfate and chondroitin 4/6-sulfate in the fractions retained and non-retained on the LDL-a⁄nity column were determined by agarose gel electrophoresis (not shown but the same methodology exempli¢ed in Fig. 1B,C ) and the quantitative results are shown in Table 3 . Dermatan sulfate from arterial wall is constituted mostly of glycosaminoglycan chains with a comparatively high a⁄nity for LDL, as a signi¢cant proportion of this compound was retained by the LDL-column. The relative content of chondroitin 4/6-sulfate, on the other hand, decreased in inverse relation, which indicates that chains with a comparatively low a⁄n-ity for LDL are the major constituents of this glycosaminoglycan. In contrast, for the glycosaminoglycans from the venous wall the proportion of dermatan sulfate and chondroitin 4/6-sulfate did not vary dramatically between the fraction with and without af¢nity for LDL.
Combining the data of the proportions of glycosaminoglycan retained and non-retained on the LDL-a⁄nity column (Table 2) , the relative proportions of dermatan sulfate and chondroitin 4/6-sul- The contents of dermatan sulfate (DS) and chondroitin 4/6-sulfate (CS) with and without a⁄nity for LDL (as Wg of hexuronic acid/ mg of dry, defatted tissue) were determined combining the data of the proportions of the two glycosaminoglycan retained and not-retained on the LDL-column (Fig. 3 , Table 2 ) with those of relative proportions (Table 3 ) and total content of the glycosaminoglycans in the vessels (Fig. 2) . The relative amounts of dermatan sulfate (DS) and chondroitin 4/6-sulfate (CS) retained and non-retained on an LDL-a⁄nity column were determined by agarose gel electrophoresis, as exempli¢ed in Fig. 1B ,C.
fate in fractions with and without a⁄nity for LDL (Table 3) with those for total glycosaminoglycan contents ( Fig. 2 ) allowed us to estimate the concentrations of dermatan sulfate and chondroitin 4/6-sulfate with and without a⁄nity for plasma LDL in human aorta and in the normal and varicose saphenous veins (Table 4 ). The total content of dermatan sulfate+chondroitin 4/6-sulfate retained on the LDL-a⁄nity column is V2.2-fold higher in artery than in vein. However, the content of dermatan sulfate that interact with LDL was not markedly di¡er-ent in the two types of vessels, always in the range of 0.29^0.43 Wg hexuronic acid/mg of dry, defatted tissue. In contrast, the contents of chondroitin 4/6-sulfate, both with and without a⁄nity for LDL, increase markedly from the venous to the arterial wall (approximately 4-fold more concentrated in artery than in vein). Finally, polyacrylamide gel electrophoresis of the fractions from the LDL-a⁄nity column (Fig. 4) showed that dermatan sulfate+chondroitin 4/6-sulfate that interacts with LDL always had a higher apparent molecular weight than the fractions not retained by the column. Thus, fractions retained on the LDL-column had a lower electrophoretic mobility on polyacrylamide gel than the non-retained fractions (compare lanes named R and NR in Fig. 4 ), denoting higher molecular weight of the glycan chains that interact with LDL. Nevertheless, the molecular weights of the retained glycans were somewhat variable among the venous and arterial fractions.
Discussion
Venous and arterial walls di¡er in their glycosaminoglycan content
Studies about the glycosaminoglycan content of normal and pathological arteries are abundant [39 ,18,19] , but similar analysis with veins is scarce. The preponderance of dermatan sulfate in normal saphenous veins was suggested in two previous works [20, 21] . We now performed a systematic comparison between the glycosaminoglycan contents of venous and arterial walls. Glycosaminoglycans were extracted from the tissue by proteolysis and partially puri¢ed by precipitation with a cationic detergent. After ion exchange chromatography, total glycosaminoglycan extracts yield three peaks, identi¢ed as hyaluronic acid, heparan sulfate, and a mixture of dermatan sulfate+chondroitin 4/6-sulfate (Fig. 1) .
The most abundant glycosaminoglycan in human veins is dermatan sulfate (Fig. 2B) , whereas chondroitin 4/6-sulfate is preponderant in arteries ( Fig.  2A , see also [5, 6] ). Chondroitin 4/6-sulfate and heparan sulfate are V4.8-and V2.5-fold, respectively, more concentrated in arteries than in veins whereas dermatan sulfate contents are similar in the two types of vessels. Normal and varicose saphenous veins did not di¡er in their glycosaminoglycan content. But, surprisingly, saphenous veins had a higher content of glycosaminoglycan than central veins (Table 1) due to an overall increase in the three types of sulfated glycosaminoglycans (Fig. 2) . Some di¡eren-ces between the content of glycosaminoglycans in venous wall reported by us and other authors [202 2] may be due to the methodologies used for extraction and characterization of these compounds and/or variation in the anatomic sections of the veins used in these studies.
The architecture of arterial and venous walls differs mostly due to variations in the relative amounts of basic cellular and extracellular constituents. For   Fig. 4 . Molecular weight of the dermatan sulfate+chondroitin 4/6-sulfate eluted from a LDL-a⁄nity column. Samples (10 Wg) of retained (R) and non-retained (NR) fractions from saphenous vein and thoracic aorta were run on 6% polyacrylamide gels in sodium barbital bu¡er (pH 8.6) and stained with 0.1% toluidine blue in 1% acetic acid. Molecular weight markers used were chondroitin 6-sulfate from shark cartilage (St4; average molecular weight 60 kDa), chondroitin 4-sulfate from whale cartilage (St3; average molecular weight 30 kDa), dermatan sulfate from pig skin (St2; average molecular weight 20 kDa), and dextran sulfate (St1; average molecular weight 8 kDa).
example, the thicker media in the arterial rather than in venous wall may explain the dramatic di¡erence in their heparan sulfate content, which supposed to be mainly produced by the endothelial cells of the intima layer [23, 24] . But the arterial wall has also a higher chondroitin sulfate content, possibly a product from the smooth muscle cells [25] . In this case we would expect that smooth muscle cells from the two types of vessels synthesize di¡erent proportions of chondroitin 4/6-sulfate and dermatan sulfate. The drastic di¡erences we reported for the glycosaminoglycan contents of arteries and veins may also re£ect variations in the proportions of cell/extracellular matrix in these two vessels. Obviously all these possibilities require further investigation, especially concerning the question whether similar cells from the two vessels synthesize di¡erent types and/or proportions of glycosaminoglycans.
Similar proteoglycans occur in veins and arteries, although in di¡erent proportions. Thus, versican, decorin and biglycan have been reported in saphenous veins [22] . Dermatan sulfate may be attached to different proteoglycans from the vein wall. It remains to be clari¢ed which population of dermatan sulfaterich proteoglycan is particularly enriched in the venous wall.
Content of dermatan sulfate with a⁄nity for plasma LDL does not vary from artery to vein
A direct measurement of the interaction between venous glycosaminoglycans and plasma LDL was undertaken using a⁄nity chromatography. This methodology was previously used by us [3^6] and other groups [11, 26] to study the interaction between plasma LDL and the glycosaminoglycans extracted from aorta or produced by cells derived from the tissue. For this interaction with plasma LDL glycosaminoglycan chains do not require the attachment to the protein core [6] . In addition, blocking of some amino groups on the apo-B lipoprotein during the preparation of the a⁄nity column is not detrimental to use this method for detecting formation of LDL^glycosaminoglycan complexes [17] . With the use of this methodology we observed that the total content of dermatan sulfate+chondroitin 4/6-sulfate retained on the LDL-a⁄nity column is V2.2-fold higher in artery than in vein. However, this di¡erence is mostly attributed to a lower content in the venous wall of chondroitin 4/6-sulfate with a⁄nity for LDL, which is V3.86-fold more concentrated in arterial than in venous walls. In contrast, the content of dermatan sulfate that interacted with plasma LDL was not markedly di¡erent in the two types of vessels (Table 4) .
Iverius [27] observed a preferential binding of dermatan sulfate to LDL and a role of this glycosaminoglycan in the development of the atherosclerotic lesions was postulated [27, 28] . These results contrasted with other studies in which chondroitin 4/6-sulfate was shown to interact with plasma LDL [29, 30] . These apparently contradictory reports were reconciled by the observation that high-molecularweight chains of both glycosaminoglycans can interact with LDL [3, 4] . The fact that aortic dermatan sulfate constitutes most of the glycosaminoglycans with a high a⁄nity for LDL is ascribed to their comparatively longer glycan chains compared with chondroitin 4/6-sulfate [3, 4] . Unlike proteins, glycosaminoglycans occur naturally as polydisperse polymers, that is, their degree of polymerization, and hence their molecular weights, vary considerably. This parameter a¡ects binding of dermatan sulfate and chondroitin 4/6-sulfate chains to LDL [5, 6] . The fact that aortic dermatan sulfate constitutes most of the glycosaminoglycans with a high a⁄nity for LDL due to their comparatively longer glycan chains compared with chondroitin 4/6-sulfate [5, 6] .
A similar conclusion was reached in investigations on synthesis of glycosaminoglycans by arterial smooth muscle cells under di¡erent experimental conditions. In these cells, the shift from the resting to proliferating condition has been implicated in atherogenesis. This shift is accompanied by an increase in the synthesis of proteoglycans with higher a⁄nity for plasma LDL, due essentially to an increase in size of their chondroitin 4/6-sulfate chains [11] . Among the complex array of mediators taking part in atherogenesis, growth factors are capable of inducing phenotypic changes in arterial smooth muscle cells and also of increasing the synthesis of proteoglycans [31] . More important, the proteoglycans synthesized under these conditions have longer glycosaminoglycan chains [12] .
We now observed that the fraction of venous dermatan sulfate+chondroitin 4/6-sulfate retained on LDL-a⁄nity column always had a higher molecular weight than the non-retained fraction (Fig. 4) . This ¢nding extend to vein the observation about the positive correlation between the molecular size of dermatan sulfate+chondroitin 4/6-sulfate chains and interaction with LDL, although the molecular weight of the retained glycans are somewhat variable between vein and artery.
4.3.
What is the signi¢cance of the glycosaminoglycan species in venous wall with high a⁄nity for plasma LDL?
It is well established that proteoglycans and their glycosaminoglycan chains contribute to pathogenesis of atherosclerosis by retaining and modifying LDL that insudates into the arterial wall. The nature of the glycosaminoglycan^LDL interaction has been extensively studied, and it is known that certain glycosaminoglycan species, including particular populations of a given species, have greater a⁄nity for LDL. We now demonstrated that a similar population of glycosaminoglycan also occurs in the venous wall although at a lower concentration than in artery due to less chondroitin 4/6-sulfate chains with a⁄nity for plasma LDL.
Venous and arterial glycosaminoglycans were eluted from the LDL-column at NaCl concentrations below physiological level. Very high concentrations of glycosaminoglycans are found on the vessel walls. Thus, if plasma LDL binds vessel glycosaminoglycan avidly at normal salt concentration in vivo, we would expect a rapid accumulation of the lipoprotein on the vessel walls. Perhaps, this means that glycosaminoglycan chains require low-salt concentrations for binding LDL in vitro. At physiological salt concentrations, in vivo binding of glycosaminoglycan to plasma LDL probably requires additional factors, such as fusion of LDL particles [32] or certain lipases known to enhance the association of lipoproteins with smooth muscle cells and extracellular matrix [33, 34] .
Previously we demonstrated that it is unlikely that the increased risk for developing atherosclerotic lesions in older arteries results from altered glycosaminoglycan composition [6] . Possibly increasing atherosclerosis with age simply re£ects the longer time available for lipid accumulation to occur, and not changes in glycosaminoglycan composition in older arteries that favor an increased binding of LDL with age.
The presence of similar glycosaminoglycan populations with a⁄nity for plasma LDL in venous wall rise interesting questions due to the absence of atherosclerotic lesions in veins. Possibly, the presence of these glycosaminoglycan populations in the venous wall is not su⁄cient to cause endothelial dysfunction but requires additional intrinsic factors and/or the hydrodynamic of the blood under the arterial pressure. In fact, when segments of saphenous veins are transferred to the arterial system during coronary artery bypass they develop atherosclerosis [19, 20] .
Our results rise not only intrigued basic questions concerning the role of glycosaminoglycans in the pathogenesis of atherosclerosis but also have some practical aspects. Thus, vein segments (mostly from saphenous vein) are extensively used for coronary artery bypass. A long-term complication of these surgeries is the progression of atherosclerosis to the vein graft. Other types of vessels have been tested as an alternative to the saphenous vein. For example, the internal mammary artery graft has shown less longterm complications than saphenous vein graft [19] . A possible biochemical explanation for this observation is di¡erence in the content of glycosaminoglycan with high a⁄nity for LDL in the two types of vessels. Interestingly, the relative proportions of the glycosaminoglycans do not appear to modify dramatically after the transfer of saphenous vein segment to the arterial system [21] . Possibly, the methodology described in our study may constitute an appropriated way to search for more appropriated vessels for coronary bypass, less susceptible to long-term progression of atherosclerosis.
